425: Denali Capital Secures $20M PIPE for Semnur Merger

Denali Capital Acquisition Corp. announced a $20 million private investment in public equity (PIPE) financing to support its planned business combination with Semnur Pharmaceuticals, Inc.

Summary

• Denali Capital Acquisition Corp. (Denali) entered into a Securities Purchase Agreement with Semnur Pharmaceuticals, Inc. (Semnur) and a Purchaser (JW Capital Securities Limited) on August 20, 2025.
• The agreement details a Private Investment in Public Equity (PIPE) financing totaling $20,000,000.
• The Purchaser has agreed to acquire 1,250,000 shares of common stock of the combined company, to be named 'New Semnur,' at a price of $16.00 per share.
• The closing of the PIPE financing is contingent upon and expected to occur immediately following the consummation of the Business Combination between Denali and Semnur.
• Semnur's parent company, Scilex Holding Company, will deposit an aggregate of 12,000,000 shares of New Semnur common stock into an escrow account no earlier than the PIPE closing and no later than 20 business days following the Business Combination closing.
• The Business Combination is based on an Agreement and Plan of Merger, originally dated August 30, 2024, and subsequently amended, which involves Denali's domestication to Delaware and a merger with Semnur.
• The PIPE Shares will not be registered under the Securities Act of 1933, relying on exemptions for private offerings, and the Purchaser has represented itself as an accredited investor.

Sentiment

Score: 7

Explanation: The filing indicates positive progress towards the Business Combination with a significant PIPE financing secured, which is a crucial step for de-SPAC transactions. However, it also includes standard risks associated with mergers and forward-looking statements, preventing a higher score.

Positives

• Secured $20 million in additional capital for the combined entity, 'New Semnur,' through a PIPE financing, which is crucial for de-SPAC transactions.
• The PIPE financing at $16.00 per share, above the typical SPAC IPO price, demonstrates investor confidence in the valuation and prospects of the upcoming Business Combination with Semnur Pharmaceuticals.
• The Business Combination is progressing, with the Registration Statement on Form S-4 declared effective by the SEC on August 12, 2025, and the definitive proxy statement/prospectus mailed to shareholders.
• The commitment by Semnur's parent company, Scilex Holding Company, to deposit 12,000,000 shares into an escrow account may indicate long-term alignment of interests and stability for the combined company.

Negatives

• The PIPE shares are restricted securities and subject to transfer restrictions, limiting immediate liquidity for the purchaser.
• The closing of the PIPE financing and the Business Combination are subject to customary conditions, introducing execution risk.
• The Purchase Agreement includes a termination clause if the PIPE financing has not occurred on or before December 31, 2025, indicating a potential deadline pressure and risk of the deal falling through.

Risks

• General economic, political, and business conditions could adversely affect the combined company's performance.
• The inability of the parties to consummate the Business Combination or the occurrence of events that could lead to the termination of the Merger Agreement.
• Potential legal proceedings that may be instituted against the parties following the announcement of the Business Combination.
• The receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination.
• The risk that the approval of the stockholders of Semnur or the shareholders of Denali for the potential transaction is not obtained.
• Failure to realize the anticipated benefits of the Business Combination, including as a result of delays in consummating the transaction or difficulties in integrating the businesses of Semnur or Denali.
• Disruption to current plans and operations as a result of the announcement and consummation of the Business Combination.
• Challenges for the combined company to grow and manage growth profitably and to retain its key employees.
• The amount of redemption requests made by Denali's shareholders could significantly reduce the capital available to the combined company.
• The inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq or OTC Markets following the Business Combination.
• Costs related to the Business Combination may be higher than anticipated.

Future Outlook

The combined company, 'New Semnur,' anticipates future opportunities following the Business Combination. Management expects to successfully consummate the merger, but acknowledges risks related to integration, growth management, and employee retention. The ability to obtain or maintain listing of the post-acquisition company's securities on Nasdaq or OTC Markets is also a forward-looking consideration.

Management Comments

• Denali Capital Acquisition Corp. entered into a Securities Purchase Agreement with Semnur Pharmaceuticals, Inc. and the purchaser party thereto.
• The closing of the PIPE Financing is subject to customary conditions and is expected to occur immediately following the consummation of the Business Combination.
• Semnur will cause to be deposited into an escrow account an aggregate of 12,000,000 shares of New Semnur common stock beneficially owned by its parent company, Scilex Holding Company.

Industry Context

This filing reflects the ongoing trend of Special Purpose Acquisition Companies (SPACs) completing de-SPAC transactions by merging with private companies. The PIPE financing is a common mechanism to provide additional capital and validate the valuation of the target company (Semnur) in such mergers, especially in the pharmaceutical sector where capital requirements for development and commercialization are high. The involvement of a pharmaceutical company (Semnur) suggests continued activity in the biotech/pharma M&A space.

Comparison to Industry Standards

• The $16.00 per share PIPE price is above the typical $10.00 SPAC IPO price, which could indicate a premium valuation for Semnur or strong investor belief in its future prospects, though specific comparable companies or projects are not detailed in the filing.
• The requirement for Semnur's parent company, Scilex Holding Company, to escrow 12,000,000 shares is a common de-SPAC mechanism to align long-term interests and provide stability, often seen in transactions where founders or major shareholders commit to holding their equity post-merger.
• The use of a PIPE financing is a standard practice in de-SPAC transactions to raise additional capital and provide a floor for the combined entity's valuation, similar to other recent SPAC mergers in the biotechnology and healthcare sectors.

Stakeholder Impact

• Shareholders (Denali): Will vote on the Business Combination and will become shareholders of 'New Semnur' if approved. The PIPE financing provides additional capital for the combined entity.
• Shareholders (Semnur/Scilex Holding Company): Scilex Holding Company will have a significant portion of its shares escrowed, indicating a long-term commitment to the combined entity.
• Investors (PIPE Purchaser): Will acquire shares at a premium to the typical SPAC IPO price, indicating a belief in the combined company's value.
• Employees (Semnur/Denali): The Business Combination could lead to integration efforts and potential changes, but also opportunities within the larger combined entity.

Next Steps

• Consummation of the Business Combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc.
• Closing of the PIPE Financing immediately following the Business Combination.
• Deposit of 12,000,000 New Semnur common shares into an escrow account by Scilex Holding Company within 20 business days post-Business Combination closing.
• Shareholders of Denali will hold an extraordinary general meeting to approve the Business Combination.

Key Dates

Recommendation

The securing of a $20 million PIPE financing at $16.00 per share is a positive development, indicating investor confidence and providing crucial capital for the impending merger. The progress towards the Business Combination, with the S-4 declared effective and proxy materials mailed, suggests the deal is on track. However, the transaction is not yet closed, and standard risks associated with de-SPACs, such as potential shareholder redemptions, integration challenges, and the ability to achieve anticipated benefits, remain. Given the positive step but still pending completion and inherent risks, a 'hold' recommendation is appropriate for existing investors, while new investors might wait for further clarity post-merger.

Keywords

Denali Capital Acquisition Corp, Semnur Pharmaceuticals, Business Combination, Merger, PIPE Financing, Private Investment, SPAC, De-SPAC, Scilex Holding Company, New Semnur, SEC Filing, Form 8-K, Securities Purchase Agreement, Accredited Investor, Restricted Securities